A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine

NCT06291857 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

9320

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19

Interventions

BIOLOGICAL: CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant
BIOLOGICAL: Novavax COVID-19 Vaccine
BIOLOGICAL: tNIV Vaccine
BIOLOGICAL: Fluzone High Dose

Sponsor

Novavax